Requisite models for strategic commissioning: The example of type 1 diabetes

Health Care Management Science

Volumn 11, Issue 2, 2008, Pages 89-110

  Airoldi, Mara ^a   Bevan, Gwyn ^a   Morton, Alec ^a   Oliveira, Mónica ^b   Smith, Jenifer ^c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Commissioning; DALYs; Intensive glucose control; Microvascular complications; Population health; QALYs; Resource allocation; Strategic purchasing; Type 1 diabetes

Indexed keywords

AGE DISTRIBUTION; ARTICLE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMICS; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

AGE DISTRIBUTION; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; HEALTH CARE RATIONING; HUMANS; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 43149083886     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10729-008-9056-9     Document Type: Article

References (100)

1. Ross J (1995) The use of economic evaluation in health care: Australian decision makers' perceptions. Health Policy 31:103-110
2. Drummond MF, Cooke J, Walley T (1997) Economic evaluation under managed competition: evidence from the U.K. Soc Sc Med 45(4):583-595
3. Duthie T et al (1999) Research into the use of health economics in decision making in the United Kingdom-Phase II Is health economics 'for good or evil'? Health Policy 46:143-157
4. Drummond MF, Weatherly H (2000) Implementing the findings of health technology assessments. If the CAT got out of the bac, can the TAIL wag the dog? Int J Technol Assess Health Care 16(1):1-12
5. Bryan S, Williams I, McIver S (2007) Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Econ 16:179-193
6. Department of Health. PCT and SHA roles and functions (2006) http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_4134649. Cited January 8, 2008
7. Local Health System Integration Act (2006), Ontario
8. Weinstein M, Stason W (1977) Foundation of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716-721
9. Williams A (1985) Economics of coronary artery bypass grafting. Br Med J 291:326-329
10. Gold MR et al. (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
11. Drummond MF, et al (2005) Methods for the economic evaluation of health care programmes, third edition. Oxford University Press, Oxford
12. Anand S, Hanson K (1997) Disability-adjusted life years: a critical review. J Health Econ 16(6):685-702
13. Williams A (1999) Calculating the global burden of disease: time for a strategic reappraisal. Health Econ 8:1-8
14. Mooney G, Wiseman V (2000) Burden of disease and priority setting. Health Econ 9:369-372
15. Bevan G, Hollinghurst S (2003) Cost per quality adjusted life year and disability adjusted life years: the need for a new paradigm. Expert Rev Pharmacoecon Outcomes Res 3(4):469-477
16. Murray CJL, Acharya AK (1997) Understanding DALYs. J Health Econ 16:703-730
17. Murray CJL, Lopez AD (2000) Progress and directions in refining the Global Burden of Disease approach: a response to Williams. Health Econ 9:69-82
18. Lopez AD et al (2002) Summary measures of population health: concepts, ethics, measurement and application. World Health Organization, Geneva
19. Hutubessy R, et al. (2003) Generalised cost-effectiveness analysis for national-level priority setting in the health sector. Cost Eff Resour Alloc 1:8
20. Andrews G et al (2004) Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 184:526-533
21. Evans D et al (2005) Methods to assess the costs and health effects of interventions for improving health in developing countries. Br Med J 331:1137-1140
22. Dawson D, et al (2005) Developing new approaches to measuring NHS outputs and productivity. Report RP6, University of York Centre for Health Economics, York
23. Department of Health (2005) Healthcare output and productivity: accounting for quality change. http://www.dh.gov.uk/PublicationsAndStatistics/ Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/ fs/en?CONTENT_ID=4124266&chk=5QmbY7
24. UK Centre for the Measurement of Government Activity (2006) Public service productivity: health. Econ Trends 628:26-57
25. Martin S, Smith PC (2006) Value for money in the NHS. A summary of the evidence. C.f.H. Economics, Editor, University of York, York
26. Evans D et al (2005) Time to reassess strategies for improving health in developing countries. Br Med J 331:1133-1136
27. Hollinghurst S, Bevan G, Bowie C (2000) Estimating the "avoidable" burden of disease by Disability Adjusted Life Years (DALYs). Health Care Manage Sci 3(1):9-21
28. Hollinghurst S, Bevan G (2003) A scientific revolution to resolve the incomplete paradigms of cost per quality adjusted life year and disability-adjusted life-years? Expert Rev Pharmacoecon Outcomes Res 3(4):469-77
29. Bevan G et al (1998) The South and West DALYs Project-developing a powerful tool for health care planning. Somerset Health Authority, Taunton
30. Rutstein D (1976) Measuring the quality of medical care. A clinical method. N Engl J Med 294(11):582-588
31. Charlton J et al (1983) Geographical variation in mortality from conditions amenable to medical intervention in England and Wales. The Lancet 321(8326):691-696
32. Holland, W (1991) European Community Atlas of 'Avoidable Death'-Commission of the European Communities Health Services Research Series no. 6. Second edn, Vol. 1. In: W. Holland (ed). Oxford University Press, Oxford
33. Andrews G et al (2004) Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 184:526-533
34. Tan-Torres Edejer T (2003) Making choices in health: WHO guide to cost-effectiveness analysis. W.H. Organization, Geneva
35. Dawson D, et al (2005) Developing new approaches to measuring NHS outputs and productivity. CHE Research Paper (6). Centre for Health Economics, York, UK
36. Tomar R, et al (1998) Disease progression and cost of insulin dependent diabetes mellitus: development and application of a simulation model. J Soc Health Syst 5(4):24-37
37. Herman W et al (1997) The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinol Metab Clin N Am 26(3):679-695
38. Palmer A et al (2000) The cost-effectiveness of different management strategies for Type I diabetes: a Swiss perspective. Diabetologia 43(1):13-26
39. Diabetes Control and Complication Trial (1996) Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 276(17):1409-415
40. Forouhi N et al (2006) Diabetes prevalence in England, 2001-estimates from an epidemiological model. Diabet Med 23(2):189-197
41. National Clinical Audit Support Programme. National Diabetes Audit (2005) Key findings about the quality of care for people with diabetes in England. Report for the audit period 2003/04. http://www.icservices.nhs.uk/ncasp/pages/ audit_topics/diabetes/default-new.asp
42. Diabetes Control and Complication Trial (1990) Diabetes control and complication trial update. Diabetes Care 13(4):427-433
43. Diabetes Control and Complication Trial (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977-986
44. Eastman J et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20(5):735-744
45. Gray A et al (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373-1378
46. Stouthard M, et al (1997) Disability weights for diseases in The Netherlands. Rotterdam: Erasmus University, Department of Public Health
47. National Institute for Health and Clinical Excellence (2007) The guidelines manual 2007. http://www.nice.org.uk/page.aspx?o=422950
48. Wood I, Mallick N, Wing A (1987) Prediction of resources needed to achieve the national target for treatment of renal failure. BMJ 294:1467-1470
49. Bagust A et al (2002) The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabet Med 19(Supplement 4):1-5
50. Fanshel S, Bush J (1970) A health-status index and its application to health-services outcomes. Oper Res 18(6):1021-1066
51. Eastman R (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20(5):725-734
52. Palmer A et al (2004) The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (type 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 20(Suppl. 1):S5-S26
53. Mueller E, et al (2006) Development and validation of the economic assessment of glycemic control and long-term effects of diabetes (EAGLE) model. Diabetes Technol Ther 8(2):219-236
54. Eddy DM, Schlessinger L (2003) Archimedes: a trial-validated model of diabetes. Diabetes Care 26:3093-3101
55. Pidd M (2003) Tools for thinking. Modelling in management science, second edn. Wiley, Chichester
56. Phillips L (1984) A theory of requisite decision models. Acta Psychol 56:29-48
57. Morgan C et al (2000) The prevalence of multiple diabetes-related complications. Diabet Med 17:146-151
58. Department of Health (2004) Population figures at SHA and PCO level for England and Wales. www.dh.gov.uk/assetRoot/04/11/36/62/04113662.xls
59. Harvey J, Craney L, Kelly D (2002) Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: comparison of record linkage with capture-recapture analysis. J Epidemiol Commun Health 56:18-23
60. Laing S et al (1999) The British Diabetic Association Cohort Study, I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16(6):459-465
61. Laing S et al (1999) The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16(6):466-471
62. Soedamah-Muthu S et al (2006) All-cause mortality rates in patients with Type 1 diabetes mellitus compared to a non-diabetic population from the General Practice Research Database (GPRD) 1992-1999. Diabetologia 49(4):660-666
63. Soedamah-Muthu S et al (2006) High Risk of Cardiovascular Disease in Patients with Type 1 Diabetes in the U.K. A cohort study using the General Practice Research Database. Diabetes Care 29(4):798-804
64. Rossing P et al (1996) Predictors of mortality in insulin dependend diabetes: 10-year observational follow-up study. Br Med J 313:779-784
65. Borch-Johnsen K, Andersen P, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596
66. Moss S, Klein R, Klein B (1992) The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 152:610-616
67. Thompson D, Kozak S, Sheps S (1999) Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients: a randomized trial. Can Med Assoc J 161:959-962
68. Currie C et al (1997) NHS acute sector expenditure for diabetes: the present, future, and excess in-patient cost of care. Diabet Med 14(8):686-692
69. Ansell D et al (2003) UK Renal Registry. The Sixth Annual Report. The Renal Association, Bristol
70. Williams R et al (2004) Epidemiology of diabetic retinopathy and macula oedema: a systematic review. Eye 18:963-983
71. Davies R et al (2000) Using simulation modelling for evaluating screening services for diabetic retinopathy. J Oper Res Soc 51:476-484
72. Mount Hood 4 Modeling Group (2007) Computer modeling of diabetes and its complications. Diabetes Care 30(6):1638-1646
73. Ortegon MM, Redekop WK, Niessen LW (2004) Cost-effectiveness of prevention and treatment of the diabetic foot. A Markov analysis. Diabetes Care 27:901-907
74. Currie C et al (2007) The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 24:187-194
75. Gordois A et al (2004) The health care costs of diabetic nephropaty in the United States and the United Kingdom. J Diabetes Complicat 18:18-26
76. Gordois A et al (2003) The health care costs of diabetic peripheral neuropathy in the United Kingdom. The Diabetic Foot 6:62-73
77. Klein R (1994) The Wisconsin Epidemiologic study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112:1217-1228
78. Klein R (1998) The Wisconsin Epidemiologic Study of Diabetic Retinopathy XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type1 diabetes. Ophthalmology 102:1799-1800
79. Klein R (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237-243
80. Klein R (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is greater than 30 years. Arch Ophthalmol 107:244-249
81. Klein R et al (1989) Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med 149:266-267
82. Colquitt J, et al. (2004) Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 8(43):1-186
83. MacLeod A, et al. (1998) Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. Health Technol Assess 2(5):1-166
84. Williams A (2004) What could be nicer than NICE? Office of Health Economics, London
85. Bevan, G., et al (2007) Estimating health and productivity gains in England from selected interventions. Research report, The Health Foundation
86. Diabetes UK (2004) The national paediatric diabetes audit. Results from the audit year 2002. http://www.bsped.org.uk/professional/diabetesuk/ NationalPaediatricAudit.pdf
87. Diabetes UK (2004) Diabetes in the UK 2004. A report from Diabetes UK
88. Health and Social Care Information Centre (2004) Quality and Outcomes Framework. http://www.ic.nhs.uk/services/qof
89. Brailsford S et al (1998) Evaluating screening policies for the early detection of retinopathy in patients with non-insulin dependent diabetes. Health Care Manage Sci 1:115-124
90. Brailsford S et al (2001) Screening for diabetic retinopathy. The evaluation of screening policies for diabetic retinopathy using computer simulation. http://www.management.soton.ac.uk/retinopathy/ last updated 25 October 2001. Date of last access 13 November 2007
91. Davies R et al (2000) Using simulation modelling for evaluating screening services for diabetic retinopathy. J Oper Res Soc 51: 476-484
92. Niessen L (2002) Roads to health. Multi-state modelling of population health and resource use. Dutch University Press
93. Office of National Statistics (2003) Mortality statistics. Cause. Series DH2, no. 30
94. Mowatt G et al (2003) Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess 7(2)
95. Clarke P et al (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS study No. 65). Diabetic Medicine 20:442-450
96. Harvey, J et al (2001) Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes. Diabet Med 18:998-1002
97. DARTS (2001) DARTS annual report, Tayside: Tayside University Hospital
98. Finne P et al (2005) Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 294(14):1782-1787
99. Klein R et al (1984) The Wisconsin Epidemiologic study of diabetic retinopathy. Arch Ophthalmol 102:520-526
100. HM Treasury (2003) The Green Book: appraisal and evaluation in central Government. London: TSO